Pharmaceutical research firm Best Practices, LLC, US, has released a new report titled 'Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance'. According to the report, the landscape of scientific publications strategy, planning and delivery is changing with the advent of transparency guidelines. It further states that half of global publications groups are fully located in the marketing function, but publications leaders forecast a shift to medical groups to increase clinical presentation.
The study included companies such as Pfizer, GlaxoSmithKline, Lilly and Merck. It was found that 14 percent of participating pharmaceutical and biotech companies avoid using global or regional marketing representatives to develop their global publications strategy. These companies, which align publications strictly within the medical group, receive strategic input from medical directors, advisor physicians and biostatisticians.
The study guides pharmaceutical and biotechnology companies in the transition to the new publishing environment to create the desired synergy between credibility of scientific rigor and increased commercial success. Among the key topics gathered in this report are centralisation of publications strategy, planning and delivery; trends surrounding regional strategy contribution; strategies for publishing neutral/negative results; outsourcing of global publications resources; and measures used for performance evaluation. A complimentary summary of the full report is available at http://www3.best-in-class.com/rr946.htm.
